Explore BioBoost LabsBio T/2
A dual-receptor engineered incretin peptide designed to engage both the GIP and GLP-1 receptors, used as a research reference for combined incretin signaling.
One class, three reaches
Bio S/1, Bio T/2 and Bio R/3 are all incretin-class research peptides. What separates them is simple — how many of these three receptors each one engages.
GLP-1 receptor agonist
GIP / GLP-1 co-agonist
GLP-1 / GIP / glucagon agonist
An incretin receptor studied for its role in glucose-dependent insulin release, slowed gastric emptying, and satiety signaling.
The second incretin receptor, studied for insulin secretion and how the body handles lipids and adipose tissue.
Studied for hepatic glucose output and energy expenditure — the third lever the triple agonist adds.
single
Engages the GLP-1 receptor only. The foundational, single-target member of the class — the most studied of the three, and the reference the dual and triple agonists are compared against.
dual
Engages GLP-1 and GIP together — one peptide activating both incretin receptors. Investigated for whether combining the two incretin signals behaves differently from GLP-1 alone.
triple
Engages all three — GLP-1, GIP, and the glucagon receptor. Adding the glucagon arm brings hepatic glucose handling and energy expenditure into the mechanism. The broadest-reach member of the class, and the newest and least studied.
Research-use-only educational content. Receptor pharmacology is described as investigated in the peer-reviewed literature — not dosing, medical, or treatment guidance, and not a claim of any effect in humans. Compounds shown by their BioBoost research codes; no brand names used.
What the name means
Bio T/2 is an internal code, not a brand or generic name. The “2” captures its defining pharmacology: it is a dual-receptor agonist.
Those two targets are the GIP and GLP-1 receptors — the two incretin axes. Bio T/2 therefore denotes the two-receptor member of the incretin family, sitting between the single-target and triple-target designs. The name is a class descriptor.
What it actually is
Bio T/2 is a single-chain synthetic peptide engineered to act at two receptors at once, on the size scale of the natural incretin hormones (roughly forty amino-acid residues).
Type Engineered dual incretin agonist
Length ~40 residues (incretin scale)
Modification Fatty-acid acylation for extended lifetime
Origin GLP-1 / incretin biology
To avoid fingerprinting any specific commercial molecule, this log keeps the length approximate and does not print a full sequence. The concept is a hybrid incretin backbone tuned to recognize both the GIP and GLP-1 receptors.
Where it came from
GIP and GLP-1 are the body’s two incretin hormones, both released from the gut after eating and both feeding into glucose-dependent insulin signaling. Native versions are short-lived.
The engineering that made long-acting incretin peptides possible traces to the Gila monster (Heloderma suspectum) and its venom peptide exendin-4, a GLP-1-like molecule naturally resistant to rapid breakdown. That insight — how to keep incretin activity while extending lifetime — underlies the whole engineered class, including dual GIP/GLP-1 designs like Bio T/2.
Why it was created — the thought process
The design idea behind a dual agonist is that the two incretin axes are complementary. Combining GIP and GLP-1 activity in one long-acting peptide creates a research tool for studying how the two pathways interact in glucose and energy-balance signaling.
Building the molecule to be long-acting — via backbone stabilization and acylation — lets that combined signaling be observed over an extended window. This log presents Bio T/2 as an investigational research concept and makes no benefit or outcome claim.
How it is made
Dual-agonist peptides are assembled by solid-phase peptide synthesis or produced by recombinant expression, then purified.
A fatty-acid chain is attached (acylation) to enable albumin binding and slow clearance, giving the long-acting profile. Purification is typically by HPLC with mass-spectrometric identity confirmation.
What the research actually shows — honestly
Across the dual GIP/GLP-1 class, what has been studied is combined receptor engagement and downstream signaling — glucose-dependent insulin secretion and satiety-related pathways — described here strictly as mechanism.
This is research-use-only reference material. No efficacy or health claims are made, and no dosing, timing, or protocol is provided. Mechanistic findings in models do not establish a clinical outcome. Direct evidence questions to a qualified physician and the peer-reviewed literature.
◆ A reference, not a recommendation
This page explains what Bio T/2 is and where it came from — the science and the story — not who should use anything, or how. These are research materials for laboratory research only; nothing here is medical, dosing, or treatment advice.
Research-use-only educational content. Factual overview; claims of clinical benefit are not implied.